- Home
- MLTX vs PHAT Comparison
MLTX vs PHAT Comparison
Compare MLTX & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MLTX | PHAT |
|---|---|---|
| Founded | 2021 | 2018 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 972.7M | 942.6M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | MLTX | PHAT |
|---|---|---|
| Price | $14.99 | $14.67 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 5 |
| Target Price | ★ $36.33 | $17.60 |
| AVG Volume (30 Days) | ★ 2.0M | 838.1K |
| Earning Date | 11-05-2025 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $147,190,000.00 |
| Revenue This Year | N/A | $218.59 |
| Revenue Next Year | N/A | $84.38 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 460.30 |
| 52 Week Low | $5.95 | $2.21 |
| 52 Week High | $62.75 | $16.27 |
Technical Indicators
Market Signals| Indicator | MLTX | PHAT |
|---|---|---|
| Relative Strength Index (RSI) | 57.57 | 53.42 |
| Support Level | $12.48 | $14.61 |
| Resistance Level | $14.11 | $16.27 |
| Average True Range (ATR) | 0.77 | 0.77 |
| MACD | 0.53 | -0.10 |
| Stochastic Oscillator | 86.30 | 21.91 |
Price Performance
Historical ComparisonAbout MLTX MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.